UNSPSC 51434917: Bisoprolol/hydrochlorothiazide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434917 Bisoprolol/hydrochlorothiazide is a Commodity code representing a single pharmaceutical product line that state and local governments acquire as part of broader emergency medical and pharmacy benefit programs. The code encompasses acquisition of this specific antihypertensive combination medication through public health, emergency services, and state pharmacy channels. State and local buyers soliciting under this code include municipal fire and rescue departments, state health and human services agencies, and cooperative purchasing alliances serving multi-state public sector networks. Recent activity shows emergency medical services procurement (Tampa Fire Rescue's Advanced Life Support Medications bid) and state-level pharmacy benefit program development (Texas HHS Commission's Therapeutic Pharmacy Initiative exploration and Minnesota's multistate cooperative pharmaceutical contracting). The scope extends beyond bisoprolol/hydrochlorothiazide alone—jurisdictions are acquiring multiple emergency medications and building direct-to-manufacturer or wholesaler-distributed pharmacy supply chains, with formal competitive bidding (IFB), requests for information (RFI), and cooperative RFP mechanisms all in use.

Geographic activity concentrates in Florida, Texas, and Minnesota with multistate reach through cooperative purchasing. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications on April 24, 2026, with a response deadline of April 8, 2026, seeking 370 units of Labetalol HCI, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem at an estimated value of $40,000, with a one-year contract term and two optional one-year renewals, restricted to lowest responsive bidder and sheltered 5 percent SLBE discount not to exceed $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, with response deadline March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed through three authorized wholesalers across Minnesota and Oregon, with two-year initial contract terms and performance penalties of $200 to $1,500 per violation. Texas HHS Commission issued RFI HHS0017013 in March 2026 to explore vendor capabilities for direct-to-manufacturer prescription fulfillment as preliminary market research preceding formal procurement.